ABSTRACT Background
INTRODUCTION
Treatments for psychosis have been in wide use for nearly half a century, yet there is little evidence that they have substantially improved outcomes 1 . Therefore, indicated preventative treatment in psychosis is the main paradigm yielding new hope for impacting the course of psychosis 2 . However, preventative treatment of psychosis requires first an accurate diagnosis of individuals at clinical high risk (CHR hereafter) that relies on the use of accurate prognostic tools to detect psychosis as early as possible so that its progress can be arrested and, if possible, reversed.
Prognostic testing is commonly used in preventative medicine 3 . While a screening test should identify all individuals who may develop the disease 4 , a prognostic test is used to predict the presence or absence of the future disease when a patient shows some heralding signs or symptoms of the disease. Examples of predictive testing in somatic medicine include fasting glucose and oral glucose tolerance test and glycated haemoglobin to detect subjects at high risk for diabetes (prediabetes or intermediate hyperglycaemia) 5 . Prediabetes closely resembles the CHR state in that only about 5-10% of people per year will progress to diabetes, with the same proportion converting back to normoglycaemia 5 . Since no biological test such as those used to detect prediabetes are available in clinical psychiatry 6 , for an indicated prevention of psychosis, prognostic testing is usually accomplished by administration of specific psychometric interviews, which assess validated CHR criteria 7 . These instruments include the Comprehensive Assessment of At Risk Mental State (CAARMS) 8, 9 , the Structured Interview for Psychosis-Risk Syndrome (SIPS) 10 and the Basel Screening Instrument for Psychosis (BSIP) 11 for the assessment of 'ultra-high risk' (UHR) criteria 12 , and the Bonn Scale for the Assessment of Basic Symptoms (BSABS) 13 and, developed from it, the Schizophrenia Proneness Instruments (Adult Version, SPI-A 14 , and Child & Youth version, SPI-CY 15 ) for the assessment of basic symptom (BS) criteria 16 . The UHR criteria include attenuated psychotic symptoms (APS), brief limited intermittent psychotic symptoms (BLIPS) and trait vulnerability plus a marked decline in psychosocial functioning (Genetic Risk and Functional Deterioration Syndrome: GRFD). The two partially overlapping BS criteria rely on subjectively experienced disturbances of perception, thinking, language and attention 17 .
These CHR instruments show excellent reliability in trained raters: the overall inter-rater agreement for the SIPS was 0.95 18 , for the CAARMS 0.85 12 and for the SPI-A 0.91 19 . Yet, their prognostic accuracy is still uncertain. For an ideal instrument, all subjects actually about to develop psychosis should be classified as "at risk" (CHR+) while those suffering from other complaints not leading to frank psychosis should be classified as "not at risk" (CHR-). 24 . Conversely, the predictive value and potential clinical utility of these instruments in samples with a lower prevalence of the condition, such as the general population, still await results from follow-ups [25] [26] [27] . Similarly, the predictive value in other samples with a variable psychosis risk such as unselected psychiatric adolescents 28 , subjects accessing public treatment services, psychiatric patients in forensic units 29 , primary care patients, genetic high risk samples, prisoners, post-partum women, 22q11.2 deletion syndrome, users of high potency cannabis, military, black ethnic minorities, refugees, borderline personality disorders or epilepsy is still largely unknown.
To overcome this lack of knowledge, we conducted the first robust meta-analysis to examine the consistency and magnitude of the prognostic accuracy of instruments used for psychosis prediction while at the same time investigating its potential clinical utility in help-seeking samples of high risk services, in the general population and across other groups.
METHODS

Search strategy
Two investigators (MC, GR) conducted a two-step literature search. At a first step, the Web of Knowledge SM database by Thomson Reuters® was searched, incorporating both the Web of Science SM and MEDLINE®. The search was extended until March 2015, including abstracts in English language only. The electronic research adopted several combinations of the following keywords: "at risk mental state", "psychosis risk", "prodrome", "prodromal psychosis", "ultra-high risk", "high risk", "help-seeking", "diagnostic accuracy", "sensitivity", "specificity", "psychosis prediction", "psychosis onset" and name of the possible CHR assessment instruments. The second step involved the use of Scopus® to investigate citations of previous systematic reviews on transition outcomes in CHR subjects and a manual search of the reference lists of the retrieved articles. Articles identified through these two steps were then screened for the selection criteria on basis of abstract reading. The articles surviving this selection were assessed for eligibility on basis of full-text reading. To achieve a high standard of reporting, we adopted the MOOSE checklist 30 (available from the authors on request).
Selection criteria
Studies were eligible for inclusion if the following criteria were fulfilled: (a) were original articles, written in English or in German; (b) have screened the same pool of referrals with an established CHR psychometric instrument (index test) 7 (i.e. APS, BLIPS, GRFD or BS); (c) have followed up both CHR+ and CHR for psychosis onset (reference index) with established international diagnostic manuals (ICD/DSM); (d) have reported sufficient prognostic accuracy data. With respect to the latter point, when data were not directly presented they were indirectly extracted from associated data. Additionally, we contacted all corresponding authors to request additional data when needed.
Exclusion criteria were: (a) abstracts, pilot datasets, reviews, articles in language other than English and German; (b) articles that were not interviewing the same pool of referrals or that used an external CHR-group of healthy controls; (c) articles with overlapping datasets.
Specifically, in case of multiple publications deriving from the same study population, we selected the articles reporting the largest and most recent data set. Literature search was summarized according to the PRISMA guidelines 31 .
Recorded variables
Data extraction was independently performed by two investigators (MC, GR): author, year of publication, characteristics of CHR samples (baseline sample sizes, mean age and age range, proportion of females), the CHR diagnostic instrument used, exposure to antipsychotics, diagnostic criteria used at follow-ups to assess the psychotic outcome, follow-up time, prognostic accuracy data (number of true and false positives, true and false negatives or associated data) and quality assessment conducted with the QUADAS checklist 32 .
Statistical analysis
The statistical analysis followed the Cochrane Guidelines for Systematic Reviews of 34 .
Briefly, evaluating test accuracy requires knowledge of two quantities, the test's Se and Sp.
Meta-analysis methods for diagnostic test accuracy thus have to deal with two summary statistics simultaneously rather than one 33 . Methods for undertaking analyses which account for both Se and Sp, the relationship between them, and the heterogeneity in test accuracy, require fitting advanced hierarchical random effects models 33 .
For each study we constructed a two-by-two table, which included true positive, falsepositive, true-negative, and false-negative values. When studies reported different data at different follow-up time, we used data from the longest follow-up (please see below). The baseline sample size was conservatively used as the base reference to avoid a bias towards overly high transition risks at longer follow-ups and related higher drop-out rates of transition-negatives.
Data were then analysed with MIDAS (Meta-analytical Integration of Diagnostic Accuracy Studies) 35 , a comprehensive program of statistical and graphical routines for undertaking meta-analysis of diagnostic/prognostic test performance in STATA 13 software. The index tests of CHR status (CHR+ or CHR-) and reference tests of transition to psychosis according to international diagnostic manuals (ICD/DSM as gold standard) were dichotomous. Primary data synthesis was performed within the bivariate mixed-effects regression framework for the logit transforms of Se and Sp 35 . In addition to accounting for study size, the bivariate model estimates and incorporates the intrinsic negative correlation that may arise between Se and Sp within studies (threshold effect) 36 as a result of differences in the test threshold between studies 37 . The bivariate model allows for heterogeneity beyond chance as a result of clinical and methodological differences between studies 37 . We estimated the summary Se and Sp and the estimated hierarchical SROC curves 33 . A SROC graph across each predictor, with the yaxis representing the predictor's Se and the x-axis representing 1-specificity, was used to plot around the summary estimates a 95% confidence region and a 95% prediction region to illustrate the precision with which the summary values were estimated (confidence ellipse of a mean) and to show the amount of between-study variation (prediction ellipse; the likely range of values for a new study). We also estimated the AUC. Finally, for sensitivity analyses of the impact of follow-up times, supplementary analyses were conducted by grouping the data at each specific time point of 6, 12, 24 and ≥30 months.
Heterogeneity across studies was assessed using the I 2 , with values of 25%, 50%, and 75%
representing mild, moderate, and severe inconsistency, respectively 38 . Within MIDAS, forest plots and heterogeneity statistics can be created for each test performance parameter individually or may be displayed as paired plots. Sub-groups analyses and meta-regressions were used to examine the influence of CHR instruments used, mean age, gender (% of females), follow-up time, sample size, exposure to antipsychotics, and quality assessment (QUADAS) on meta-analytical estimates. To control for biases associated with imbalanced datasets 39 , we further tested the impact of the proportion of CHR+ in the overall samples (i.e.
CHR+ and CHR-). The meta-regressions were used if there was substantial heterogeneity (I 2 >50%) 40 . Model diagnostic analyses included quantile plot of residual based goodness-of fit; Chi-squared probability plot of squared Mahalanobis distances for assessment of the bivariate normality assumption; spike plot for checking for particularly influential observations using Cook's distance; a scatter plot for checking for outliers using standardized predicted random effects (standardized level-2 residuals) 35 . Sensitivity analyses (i.e. exclusion of outliers and rerunning of the model) were conducted to further explore heterogeneity. We did not test publication bias 41 , because no proven statistical method exists for this type of meta-analysis 42 .
In a second step we employed the probability-modifying plot and the Fagan's nomogram to estimate the clinical or patient-relevant utility of the CHR interview in subjects seeking help at early detection services, in the general population as well as in other samples (i.e. genetic high risk samples, prisoners, post-partum women, 22q11.2 deletion syndrome, users of high potency cannabis, military, black ethnic minorities, borderline personality disorders or unselected psychiatric samples). The clinical utility was evaluated using the positive and negative likelihood ratios (LR+ and LR-) to calculate post-test probability (PostTP) based on
Bayes' theorem as follows with pre-test probability (PrePT)= prevalence of condition in 35 . Specifically, the probability-modifying plot 35 , is a graphical sensitivity analysis of the test's predictive values across a baseline psychosis risk continuum in people seeking help at early detection services.
It depicts separate curves for positive and negative tests and uses general summary statistics (i.e., unconditional positive and negative predictive values, NPV and PPV, which permit underlying psychosis risk heterogeneity) to evaluate the effect of the CHR assessment on predictive values 43 . The PreTP probability of psychosis risk in subjects seeking help at early detection services was computed in the current dataset as the proportion of subjects developing psychosis on the total baseline sample (CHR+ plus CHR-) 35 . Fagan's nomogram, a two-dimensional graphical tool for estimating how much the result of a test changes the pretest probability that a patient will develop psychosis, was used to estimate the clinical value of psychometric CHR diagnostic interview in the general population and in the other samples.
Again, the clinical value is calculated on the LR+ and LR-obtained from the current metaanalysis 44 and using the pre-test psychosis risk in the different samples as estimated from the available literature.
Statistical tests were two-sided and statistical significance was defined as p-values <0.05.
RESULTS
Database
The literature review (PRISMA flow-chart available from the authors upon request) produced 11 independent studies that met the inclusion criteria, for a total of 2519 (CHR+: n=1359;
CHR-: n=1160) subjects referred to high risk services (Table 1) . Proportion of CHR+ in the total sample (CHR+ and CHR-) was 0.54 revealing an overall balanced dataset. Four studies employed the CAARMS, three the SIPS, one the BSIP, one the BSABS, and two both the SIPS and SPI-A. The mean follow-up time was 37.72 months (SD 27.81, median=33).
QUADAS ratings ranged from 2.5 to 14 (equals highest possible score), main reasons for a non-optimal rating were (partial) exposure to antipsychotics and unsatisfactory reporting of results.
*** TABLE 1 ABOUT HERE ***
Prognostic accuracy of CHR interview
Across the 11 studies interviewing help-seeking subjects for CHR symptoms, the summary meta-analytical estimate of Se and the AUC were outstanding, while the estimate of Sp was poor ( Figure 1 ). There was moderate to substantial heterogeneity for Se (I 2 =51, p=0.02) and severe heterogeneity for Sp (I 2 =95, p<0.001), 17% of which was due to threshold effects.
Sensitivity analyses revealed that the two studies with the highest proportion of CHR-in the total sample had the highest Sp 45, 46 , while the two studies with the lowest proportion of CHRhad the lowest Sp 47, 48 . However, meta-regression analyses showed that the proportion of CHR+ in the total sample had no impact on the overall AUC 39 . Across SIPS samples (n=5) 53 47, 51 and in samples combining the SIPS and SPI-A (n=1)
47
.
Meta-regression analyses revealed no significant effects for mean age, gender, follow-up time, sample size and quality assessment (QUADAS), but there was a significant effect for exposure to antipsychotics at baseline (p=0.04). This effect was driven by a significant decrease of Se (0.94) in studies (n=5) where subjects were exposed to antipsychotics as compared to studies (n=6) were subjects were not exposed (Se=0.98). Model diagnostics revealed a good fit of the model and indicated that one study was close to the outlier 
Clinical utility of psychometric CHR interviews in subjects seeking help at high risk services
The 38-month psychosis risk in the 2519 help-seeking subjects was 15% (95%CI: 0.9%-
24%). On the basis of this prior distribution, the continuous relationship between PreTP and
PostTP probability is summarized in in Figure 2 . Being CHR+ was associated with a 26% *** FIGURE 2 ABOUT HERE ***
Estimated clinical utility of psychometric CHR interviews in the general population and in other samples
Based on a lifetime prevalence of all non-organic psychotic disorders of 3.27% 60 Table 2 .
. *** TABLE 2 ABOUT HERE ***
DISCUSSION
This is the first study to present a robust and elaborated meta-analytical estimate of the prognostic accuracy of psychometric CHR interviews for psychosis prediction. Assessing help-seekers referred to a high risk service with a CHR interview generally revealed an excellent overall prognostic performance in terms of the AUC at three years (38 months) follow-up (values of 0.9-1.0 are considered outstanding, of 0.8-0.9 excellent and of 0.7-0.8 acceptable 55 ), which was comparable to other preventative approaches in medicine. However, excellent AUC values were mainly mediated by an excellent ability of the instruments to rule out psychosis (i.e., very satisfyingly low LR-and high Se), at an expense of their ability to rule in psychosis (i.e., unsatisfyingly low LR+ and only moderate overall Sp), which indicates some need to further improve prediction. Conversely, the clinical utility of current CHR instruments in non-help-seeking subjects in the general population was estimated to be low
Our first aim was to investigate at meta-analytical level the overall prognostic accuracy of CHR instruments in determining the risk of developing psychosis at three years (38 months) in young help-seeking subjects referred to high risk services. We first estimated the AUC, which serves as a global measure of test performance and indicates the overall goodness of a diagnostic tests. Thereby, we adopted a robust methodological approach following international guidelines for diagnostic/prognostic accuracy meta-analysis, to avoid the serious flaws observed in a previous meta-analytical attempt, such as overlapping samples, missing studies and lack of control for several moderators 56, 57 . Our finding of consistent prognostic accuracy across CHR instruments is particularly important, given the significant differences of operationalization criteria 58 . This finding of a negligible role of the CHR assessment instrument (i.e. CAARMS vs SIPS) is in line with our previous meta-analysis which found no differences in pooled annual transition risks between these instruments 22 . This finding was also confirmed by a second independent meta-analysis by the EPA taskforce 23 . We further revealed that despite an excellent overall prognostic accuracy there is a need to specifically improve the ability to rule in subsequent psychosis, i.e., to improve LR+ and Sp, while preserving the outstanding ability to rule it out. This is particularly relevant given that interviewing subjects seeking help at high risk services is particularly difficult: these individuals are assumed to lay on an upper mid-range of a symptomatic continuum by showing mild and often infrequent symptoms of yet some clinical significance already 25 .
However, differentiating between such gradual symptoms with specific tests or interviews is not a problem specific to psychosis prevention or other preventive approaches in psychiatry.
For example in case of the at-risk state of diabetes, the WHO proposed the use of the term "intermediate hyperglycaemia" (i.e. pre-diabetes) to accurately reflect the observation that glucose is a continuous variable and that their defined categories are based on somewhat arbitrary decisions on where to draw a line between normality and abnormality 59 . Similarly to the different cut-offs and operationalization criteria used to identify CHR subjects, the definition of pre-diabetes is based on cut-off points for glucose 5 to that there are different diagnostic operationalisations (e.g. by WHO and by the American Diabetes Association 5 ).
Furthermore, as for the CHR state 7 , progression to diabetes is not inevitable in pre-diabetes; some individuals, in the absence of any intervention may remain in that state or even revert to normoglycaemia 5 . Because of this, various risk assessment tools based on sociodemographic or questionnaire data are available to identify subjects with pre-diabetes, and their overall prognostic accuracy is comparable to our meta-analytical estimates such as the AUC=0.76
reported for the Cambridge risk score 60 . More broadly, the overall prognostic accuracy of the CHR instruments was comparable if not superior to various other medical tests used for an indicated prevention (Table 3) . However, it is important to highlight that the high AUC of CHR instruments is secondary to an accurate training of raters and on-going close supervision provided by expert clinicians 7 . Thus, the recent EPA guidance on the early detection of psychosis explicitly recommends their CHR assessment in specialized centres by well-trained raters and/or clinical supervision by such raters. discriminating CHR+ from CHR-within the same pool of help-seeking subjects referred to early detection services. Since these patients were seeking help at or were subsequently referred to early detection services and frequently presented also with psychosocial and functional impairment 61 and other non-psychotic symptoms 62 and disorders 63 (along with CHR symptoms), the use of CHR assessments should not be thought of as identifying and treating an unselected and asymptomatic group at risk of a poor outcome (universal prevention) 64 . Rather, the use of CHR assessment follows the approach of an indicated prevention, which is concerned with detecting a disease in its earliest stages, before frank symptoms appear, and with intervening to slow or stop its progression into the full-blown medical picture. Therefore, recent EPA guidance explicitly restricts CHR assessment to the clients of mental health services 23 . With regard to the potential CHR+ misdiagnosis of persons who do not in fact develop psychosis, or the potential CHR-misdiagnosis of persons who will develop psychosis, the low Sp suggests a stepped and multi-component strategy. In a first sensitivity-preserving step, CHR instruments could be used to rule out true negatives,
i.e. subjects who are unlikely to develop psychosis. In a second step, additional clinical, neurocognitive, biological or combined models of risk stratification could be applied to the CHR+ group with the aim of increasing Sp and prognostic reliability. This would enable risk stratification and personalized treatments accordingly 65, 66 .
We further estimated the clinical utility of CHR assessments in other clinical and non-clinical populations as clinical utility is affected by the underlying psychosis risk in a population. In particular, the conditional probability of a condition given a positive or negative test result, the so-called PPV and NPV values are critically important for clinical applications, and the PPV tends to be highest in settings with a high prevalence of the disorder 4 . We found that testing positive for CHR was associated with a 26% risk of developing psychosis within three years (38 months), a number comparable with our previous meta-analysis (95CI% 23 -35) 22 of transition risks in CHR+ subjects. This was due to a small LR+ of 1.82 54 . We could also show here for the first time that being CHR-was associated with only a 1.56% risk of 29 . Conversely, our estimates provide some support for the clinical utility of CHR assessments in subjects with two psychotic relatives, in patients with 22q11.2 deletion syndrome and in subjects using high potency cannabis, as well as for preventative trials already proposed in some of these clinical samples 68 . The additional novel finding is that our probability-modifying plot allows future power calculation studies in variable samples characterized by an underlying variable psychosis risk that is ranging from 0 to 1. For example, with our plot available, the researchers may draw a vertical line from the selected pre-test probability of the sample to the appropriate likelihood ratio line and then reads the post-test probability off the vertical scale.
Some limitations should be acknowledged. First, because of limited statistical power, we were unable to directly compare the prognostic accuracy of different psychometric instruments. However, subgroups analyses revealed comparable SIPS vs CAARMS AUCs.
Furthermore, two independent meta-analyses 22, 23 did not reveal any significant impact of the type of psychometric instrument employed on risk estimates. Also, we were unable explain all the observed heterogeneity across individual studies. However, some of this was explained by threshold effects and by the effect of antipsychotics exposure on Se. An effect of age, with lower transition risks in younger CHR+ subjects was observed in our first meta-analysis 22 and recently confirmed in another re-analysis 23 . Such an age effect might have missed in our analyses, as only the by far smallest of the included studies with an only 6-month follow-up 58 was on minors only. Furthermore, the individual studies included here varied with respect to follow-up time, however, meta-regression did not reveal any significant effect. We additionally conducted supplementary analyses at each specific time points, and these analyses confirmed exceptional AUCs. Furthermore, there is new meta-analytical evidence that, in UHR samples, transition to psychosis is most likely to occur within the first 2 years after presentation to clinical services with a stable plateau after 36 months 69 . Since our mean follow-up time (38 months) falls in this plateau period, follow-up had no significant impact on the meta-analytical estimates across samples mainly at risk for UHR criteria.
CONCLUSIONS
The current prognostic accuracy meta-analysis indicated that currently used interviews for psychosis prediction have an excellent overall prognostic performance. This supports their use as clinical tool for an indicated prevention in subject seeking help at mental health services worldwide, provided raters have undergone adequate training, while discouraging their use for prevention in non-help-seeking subjects in the general population. Fagan's nomogram illustrating the meta-analytical (subjects n=2519) clinical value (posttest probability) of psychometric CHR interview in the general population in order to predict 38 months risk of psychosis, given an assumed psychosis risk (pre-test probability) of 3.27%, as reported in a nationally representative sample (n= 8028) of the general population subjects of age 30-44 year 71 . 
ACKNOWLEDGMENTS
